secwatch.observer — SEC 8-K summary
======================================

Issuer:     Emergent BioSolutions Inc. (EBS)
CIK:        0001367644
Form:       8-K
Filed at:   2024-11-06T23:59:59+00:00
Accession:  0001367644-24-000176
Event type: earnings
Sentiment:  positive
Materiality: 0.90
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Emergent BioSolutions Q3 2024 revenue $293.8M (+9% YoY), net income $114.8M, raises FY2024 guidance
--------------------------------------------------------------------------------

- Q3 2024 total revenues $293.8M, up 9% year-over-year; net income $114.8M vs loss of $263.4M in Q3 2023.
- Adjusted EBITDA surged 432% to $105.3M; company raises FY2024 revenue guidance to $1.065B-$1.125B.
- Entered new $250M term loan with OHA Agency and $100M asset-backed loan with Wells Fargo.
- Completed asset sales: RSDL product to SERB for $75M, Baltimore-Camden site for $35M, Canton warehouse for $7M.
- Received $50M from Janssen contractual dispute resolution and $30M milestone from Bavarian Nordic.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1367644/000136764424000176/0001367644-24-000176-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1367644/000136764424000176/ebs-20241106.htm
  HTML page:      https://secwatch.observer/filing/0001367644-24-000176

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer